Key result
Chemotherapy linked to ~72% lower mortality in patients with bladder angiosarcoma.
Why the study?
Bladder angiosarcoma is a rare cancer with only sporadic cases reported, and its clinicopathological features and survival outcomes are not well described.
Does chemotherapy improve survival in patients with bladder angiosarcoma?
Systematic Review (n=68)
Does chemotherapy improve survival in patients with bladder angiosarcoma?
Bladder angiosarcoma is an aggressive disease with poor survival, but chemotherapy is associated with improved prognosis.
Answers are grounded in this paper and cite their sources.
May support chemotherapy consideration in bladder angiosarcoma; leaves open prospective validation of survival benefit.
Background Bladder angiosarcoma is a rare type of cancer with only sporadic cases reported.Methods We performed a systematic review to describe clinicopathological features and survival outcomes.Results Thirty-five cases reporting 68 patients were reviewed. Among them, 35 (51.4%) were diagnosed with de novo bladder angiosarcoma and 33 (48.6%) with radiation-induced bladder angiosarcoma. The mean age at presentation was 65.255 years (±14.6), and the median tumor size was 4.6 cm (interquartile range 2.9–6.7). Hematuria was the most common symptom, reported in 52/68 patients (76.4%). Microscopic examination revealed an epithelioid-shaped morphology in 43/47 patients (91.5%), spindle-shaped cells in 13/47 (27.6%), and mixed epithelioid and spindle-shaped cells in 9/47 (19.1%). Immunohistochemical analysis showed that CD31 was positive in 36/36 patients (100%), CD34 in 17/23 (73.9%), and Factor VIII-related antigen in 17/20 (85%). Metastasis was reported in 43/60 patients (71.6%). Chemotherapy was administered to 22/68 patients (32.4%). The median follow-up time was 5 months (interquartile range 3–12). Of the 54 patients with available survival data, 16 (29.6%) survived and 38 (70.4%) died of the disease. Multivariate Cox regression analysis identified female gender (hazard ratio [HR], 2.59; P = 0.01), metastasis (HR, 2.58; P = 0.01), and chemotherapy (HR, 0.28; P = 0.01) as independent prognostic factors. No statistically significant differences in survival were observed between de novo and radiation-induced bladder angiosarcoma.Conclusions These findings suggest that BA is an aggressive disease regardless of its etiology. Early detection and timely initiation of chemotherapy may improve patient survival.
No takes yet. Share an insight, caveat, or question.
Silwal et al. (2025) conducted a systematic review in Bladder angiosarcoma (n=68). Chemotherapy vs. No chemotherapy was evaluated on Survival (HR 0.28, p=0.01). Chemotherapy was identified as an independent prognostic factor associated with improved survival in patients with bladder angiosarcoma.
Synapse has enriched 10 related papers. Consider them for comparative context: